Daniela Traini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5828512/publications.pdf

Version: 2024-02-01

239 papers	6,442 citations	61977 43 h-index	114455 63 g-index
251 all docs	251 docs citations	251 times ranked	5871 citing authors

#	Article	IF	Citations
1	Recent advances in curcumin nanoformulation for cancer therapy. Expert Opinion on Drug Delivery, 2014, 11, 1183-1201.	5.0	186
2	Strategies to Enhance Drug Absorption via Nasal and Pulmonary Routes. Pharmaceutics, 2019, 11, 113.	4.5	165
3	Combination of Silver Nanoparticles and Curcumin Nanoparticles for Enhanced Anti-biofilm Activities. Journal of Agricultural and Food Chemistry, 2016, 64, 2513-2522.	5.2	148
4	Inhalation of nanoparticle-based drug for lung cancer treatment: Advantages and challenges. Asian Journal of Pharmaceutical Sciences, 2015, 10, 481-489.	9.1	133
5	Nano- and micro-based inhaled drug delivery systems for targeting alveolar macrophages. Expert Opinion on Drug Delivery, 2015, 12, 1009-1026.	5.0	121
6	The influence of dose on the performance of dry powder inhalation systems. International Journal of Pharmaceutics, 2005, 296, 26-33.	5.2	108
7	Influence of Humidity on the Electrostatic Charge and Aerosol Performance of Dry Powder Inhaler Carrier based Systems. Pharmaceutical Research, 2007, 24, 963-970.	3.5	103
8	The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects. Expert Opinion on Drug Delivery, 2007, 4, 595-606.	5.0	102
9	Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model. Drug Development and Industrial Pharmacy, 2010, 36, 1207-1214.	2.0	98
10	The Influence of Lactose Pseudopolymorphic Form on Salbutamol Sulfateâ€“Lactose Interactions in DPI Formulations. Drug Development and Industrial Pharmacy, 2008, 34, 992-1001.	2.0	90
11	Preparation and characterisation of controlled release co-spray dried drugâ€“polymer microparticles for inhalation 2: Evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 145-152.	4.3	90
12	Co-spray-dried mannitolâ€“ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. European Journal of Pharmaceutical Sciences, 2010, 40, 239-247.	4.0	90
13	A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 83, 285-292.	4.3	86
14	Solid lipid microparticles as an approach to drug delivery. Expert Opinion on Drug Delivery, 2015, 12, 583-599.	5.0	82
15	Micro-particle corrugation, adhesion and inhalation aerosol efficiency. European Journal of Pharmaceutical Sciences, 2008, 35, 12-18.	4.0	80
16	Agglomerate Strength and Dispersion of Salmeterol Xinafoate from Powder Mixtures for Inhalation. Pharmaceutical Research, 2006, 23, 2556-2565.	3.5	76
17	Delivery of antibiotics to the respiratory tract: an update. Expert Opinion on Drug Delivery, 2009, 6, 897-905.	5.0	76
18	Liposomal Nanoparticles Control the Uptake of Ciprofloxacin Across Respiratory Epithelia. Pharmaceutical Research, 2012, 29, 3335-3346.	3.5	75

#	Article	IF	Citations
19	The Influence of Drug Morphology on Aerosolisation Efficiency of Dry Powder Inhaler Formulations. Journal of Pharmaceutical Sciences, 2008, 97, 2780-2788.	3.3	74
20	The use of computational approaches in inhaler development. Advanced Drug Delivery Reviews, 2012, 64, 312-322.	13.7	69
21	Cospray Dried Antibiotics for Dry Powder Lung Delivery. Journal of Pharmaceutical Sciences, 2008, 97, 3356-3366.	3.3	67
22	Solid Lipid Budesonide Microparticles for Controlled Release Inhalation Therapy. AAPS Journal, 2009, 11, 771-778.	4.4	64
23	Brain targeting of resveratrol by nasal administration of chitosan-coated lipid microparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 250-259.	4.3	64
24	Pharmaceutical applications of the Calu-3 lung epithelia cell line. Expert Opinion on Drug Delivery, 2013, 10, 1287-1302.	5.0	63
25	Smart thermosensitive chitosan hydrogel for nasal delivery of ibuprofen to treat neurological disorders. Expert Opinion on Drug Delivery, 2019, 16, 453-466.	5.0	62
26	The Influence of Mechanical Processing of Dry Powder Inhaler Carriers on Drug Aerosolization Performance. Journal of Pharmaceutical Sciences, 2007, 96, 1331-1341.	3.3	60
27	The potential to treat lung cancer via inhalation of repurposed drugs. Advanced Drug Delivery Reviews, 2018, 133, 107-130.	13.7	57
28	Pulmonary Spray Dried Powders of Tobramycin Containing Sodium Stearate to Improve Aerosolization Efficiency. Pharmaceutical Research, 2009, 26, 1084-1092.	3.5	56
29	Surface Energy and Interparticle Force Correlation in Model pMDI Formulations. Pharmaceutical Research, 2005, 22, 816-825.	3.5	54
30	Across the pulmonary epithelial barrier: Integration of physicochemical properties and human cell models to study pulmonary drug formulations. , 2014, 144, 235-252.		54
31	The use of inverse gas chromatography for the study of lactose and pharmaceutical materials used in dry powder inhalers. Advanced Drug Delivery Reviews, 2012, 64, 285-293.	13.7	53
32	Quercetin solid lipid microparticles: A flavonoid for inhalation lung delivery. European Journal of Pharmaceutical Sciences, 2013, 49, 278-285.	4.0	53
33	Application of RPMI 2650 nasal cell model to a 3D printed apparatus for the testing of drug deposition and permeation of nasal products. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 107, 223-233.	4.3	53
34	Controlled release antibiotics for dry powder lung delivery. Drug Development and Industrial Pharmacy, 2010, 36, 119-126.	2.0	51
35	Deposition, Diffusion and Transport Mechanism of Dry Powder Microparticulate Salbutamol, at the Respiratory Epithelia. Molecular Pharmaceutics, 2012, 9, 1717-1726.	4.6	51
36	Particle Aerosolisation and Break-up in Dry Powder Inhalers 1: Evaluation and Modelling of Venturi Effects for Agglomerated Systems. Pharmaceutical Research, 2010, 27, 1367-1376.	3.5	50

#	Article	IF	Citations
37	The nanoscale in pulmonary delivery. Part 2: formulation platforms. Expert Opinion on Drug Delivery, 2007, 4, 607-620.	5.0	49
38	Lactose Composite Carriers for Respiratory Delivery. Pharmaceutical Research, 2009, 26, 802-810.	3.5	49
39	Ciprofloxacin Is Actively Transported across Bronchial Lung Epithelial Cells Using a Calu-3 Air Interface Cell Model. Antimicrobial Agents and Chemotherapy, 2013, 57, 2535-2540.	3.2	49
40	Bronchial epithelial cell extracellular vesicles ameliorate epithelialâ€“mesenchymal transition in COPD pathogenesis by alleviating M2 macrophage polarization. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 18, 259-271.	3.3	49
41	Measuring charge and mass distributions in dry powder inhalers using the electrical Next Generation Impactor (eNGI). European Journal of Pharmaceutical Sciences, 2009, 38, 88-94.	4.0	47
42	Magnetised Thermo Responsive Lipid Vehicles for Targeted and Controlled Lung Drug Delivery. Pharmaceutical Research, 2012, 29, 2456-2467.	3.5	47
43	In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 83-89.	4.3	46
44	Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management. Expert Opinion on Drug Delivery, 2011, 8, 1205-1220.	5.0	45
45	Epithelial Profiling of Antibiotic Controlled Release Respiratory Formulations. Pharmaceutical Research, 2011, 28, 2327-2338.	3.5	45
46	A Rifapentine-Containing Inhaled Triple Antibiotic Formulation for Rapid Treatment of Tubercular Infection. Pharmaceutical Research, 2014, 31, 1239-1253.	3.5	44
47	Primary Airâ€“Liquid Interface Culture of Nasal Epithelium for Nasal Drug Delivery. Molecular Pharmaceutics, 2016, 13, 2242-2252.	4.6	44
48	Under pressure: predicting pressurized metered dose inhaler interactions using the atomic force microscope. Journal of Colloid and Interface Science, 2003, 262, 298-302.	9.4	43
49	The influence of drug loading on formulation structure and aerosol performance in carrier based dry powder inhalers. International Journal of Pharmaceutics, 2011, 416, 129-135.	5.2	43
50	A Novel Inhalable Form of Rifapentine. Journal of Pharmaceutical Sciences, 2014, 103, 1411-1421.	3.3	43
51	Overcoming Dose Limitations Using the Orbital^{Â®} Multi-Breath Dry Powder Inhaler. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2014, 27, 138-147.	1.4	42
52	The Use of Organic Vapor Sorption to Determine Low Levels of Amorphous Content in Processed Pharmaceutical Powders. Drug Development and Industrial Pharmacy, 2007, 33, 91-97.	2.0	40
53	Does carrier size matter? A fundamental study of drug aerosolisation from carrier based dry powder inhalation systems. International Journal of Pharmaceutics, 2011, 413, 1-9.	5.2	40
54	Composite carriers improve the aerosolisation efficiency of drugs for respiratory delivery. Journal of Aerosol Science, 2008, 39, 82-93.	3.8	39

#	Article	IF	Citations
55	Synthesis and Characterization of Inhalable Flavonoid Nanoparticle for Lung Cancer Cell Targeting. Journal of Biomedical Nanotechnology, 2016, 12, 371-386.	1.1	38
56	Application of a Thermosensitive In Situ Gel of Chitosan-Based Nasal Spray Loaded with Tranexamic Acid for Localised Treatment of Nasal Wounds. AAPS PharmSciTech, 2019, 20, 299.	3.3	38
57	Comparative study of erythritol and lactose monohydrate as carriers for inhalation: Atomic force microscopy and in vitro correlation. European Journal of Pharmaceutical Sciences, 2006, 27, 243-251.	4.0	36
58	The Influence of Flow Rate on the Aerosol Deposition Profile and Electrostatic Charge of Single and Combination Metered Dose Inhalers. Pharmaceutical Research, 2009, 26, 2639-2646.	3.5	36
59	Role of Agglomeration in the Dispersion of Salmeterol Xinafoate from Mixtures for Inhalation with Differing Drug to Fine Lactose Ratios. Journal of Pharmaceutical Sciences, 2008, 97, 3140-3152.	3.3	35
60	Preparation and characterisation of controlled release co-spray dried drugâ€“polymer microparticles for inhalation 1: Influence of polymer concentration on physical and in vitro characteristics. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 486-495.	4.3	35
61	Development of an Inhaled Controlled Release Voriconazole Dry Powder Formulation for the Treatment of Respiratory Fungal Infection. Molecular Pharmaceutics, 2015, 12, 2001-2009.	4.6	35
62	Co-spray dried resveratrol and budesonide inhalation formulation for reducing inflammation and oxidative stress in rat alveolar macrophages. European Journal of Pharmaceutical Sciences, 2016, 86, 20-28.	4.0	35
63	Preparation and Evaluation of Controlled Release Microparticles for Respiratory Protein Therapy. Journal of Pharmaceutical Sciences, 2009, 98, 2709-2717.	3.3	34
64	Development and Evaluation of Paclitaxel and Curcumin Dry Powder for Inhalation Lung Cancer Treatment. Pharmaceutics, 2021, 13, 9.	4.5	34
65	In Vitro Cell Integrated Impactor Deposition Methodology for the Study of Aerodynamically Relevant Size Fractions from Commercial Pressurised Metered Dose Inhalers. Pharmaceutical Research, 2014, 31, 1779-1787.	3.5	33
66	Inhaled gene delivery: a formulation and delivery approach. Expert Opinion on Drug Delivery, 2017, 14, 319-330.	5.0	33
67	The utility of 3D-printed airway stents to improve treatment strategies for central airway obstructions. Drug Development and Industrial Pharmacy, 2019, 45, 1-10.	2.0	33
68	Introduction of the Electrical Next Generation Impactor (eNGI) and Investigation of its Capabilities for the Study of Pressurized Metered Dose Inhalers. Pharmaceutical Research, 2009, 26, 431-437.	3.5	32
69	In vitro biological activity of resveratrol using a novel inhalable resveratrol spray-dried formulation. International Journal of Pharmaceutics, 2015, 491, 190-197.	5.2	32
70	Dry powder nasal drug delivery: challenges, opportunities and a study of the commercial Teijin Puvlizer Rhinocort device and formulation. Drug Development and Industrial Pharmacy, 2016, 42, 1660-1668.	2.0	32
71	In Vitro Investigation of Drug Particulates Interactions and Aerosol Performance of Pressurised Metered Dose Inhalers. Pharmaceutical Research, 2006, 24, 125-135.	3.5	30
72	A review of co-milling techniques for the production of high dose dry powder inhaler formulation. Drug Development and Industrial Pharmacy, 2017, 43, 1229-1238.	2.0	29

#	Article	IF	Citations
73	Nanotoxicologic Effects of PLGA Nanoparticles Formulated with a Cell-Penetrating Peptide: Searching for a Safe pDNA Delivery System for the Lungs. Pharmaceutics, 2019, 11, 12.	4.5	29
74	The Use of AFM and Surface Energy Measurements to Investigate Drug-Canister Material Interactions in a Model Pressurized Metered Dose Inhaler Formulation. Aerosol Science and Technology, 2006, 40, 227-236.	3.1	28
75	Modifying and Integrating in vitro and ex vivo Respiratory Models for Inhalation Drug Screening. Frontiers in Bioengineering and Biotechnology, 2020, 8, 581995.	4.1	28
76	Investigation into the influence of polymeric stabilizing excipients on inter-particulate forces in pressurised metered dose inhalers. International Journal of Pharmaceutics, 2006, 320, 58-63.	5.2	27
77	Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability. Expert Opinion on Drug Delivery, 2016, 13, 183-193.	5.0	27
78	The effect of ethanol on the formation and physico-chemical properties of particles generated from budesonide solution-based pressurized metered-dose inhalers. Drug Development and Industrial Pharmacy, 2013, 39, 1625-1637.	2.0	26
79	Towards the bioequivalence of pressurised metered dose inhalers 1: Design and characterisation of aerodynamically equivalent beclomethasone dipropionate inhalers with and without glycerol as a non-volatile excipient. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 31-37.	4.3	26
80	Scanning White-Light Interferometry as a Novel Technique to Quantify the Surface Roughness of Micron-Sized Particles for Inhalation. Langmuir, 2008, 24, 11307-11312.	3.5	25
81	Particle Aerosolisation and Breakâ€up in Dry Powder Inhalers: Evaluation and Modelling of the Influence of Grid Structures for Agglomerated Systems. Journal of Pharmaceutical Sciences, 2011, 100, 4710-4721.	3.3	25
82	Combined Inhaled Salbutamol and Mannitol Therapy for Mucus Hyper-secretion in Pulmonary Diseases. AAPS Journal, 2014, 16, 269-280.	4.4	25
83	An update on the use of rifapentine for tuberculosis therapy. Expert Opinion on Drug Delivery, 2014, 11, 421-431.	5.0	25
84	Development of a Soluplus budesonide freeze-dried powder for nasal drug delivery. Drug Development and Industrial Pharmacy, 2017, 43, 1510-1518.	2.0	25
85	Particle synergy and aerosol performance in non-aqueous liquid of two combinations metered dose inhalation formulations: An AFM and Raman investigation. Journal of Colloid and Interface Science, 2011, 361, 649-655.	9.4	24
86	Cell-based therapies for the treatment of idiopathic pulmonary fibrosis (IPF) disease. Expert Opinion on Biological Therapy, 2016, 16, 375-387.	3.1	24
87	Drug delivery for tuberculosis: is inhaled therapy the key to success?. Therapeutic Delivery, 2017, 8, 819-821.	2.2	24
88	Engineered nasal dry powder for the encapsulation of bioactive compounds. Drug Discovery Today, 2022, 27, 2300-2308.	6.4	24
89	Does electrostatic charge affect powder aerosolisation?. Journal of Pharmaceutical Sciences, 2010, 99, 2455-2461.	3.3	23
90	Pharmacopeial methodologies for determining aerodynamic mass distributions of ultra-high dose inhaler medicines. Journal of Pharmaceutical and Biomedical Analysis, 2010, 51, 853-857.	2.8	23

#	Article	IF	Citations
91	Multiple dosing of simvastatin inhibits airway mucus production of epithelial cells: Implications in the treatment of chronic obstructive airway pathologies. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 84, 566-572.	4.3	23
92	Fluticasone uptake across Caluâ€3 cells is mediated by salmeterol when deposited as a combination powder inhaler. Respirology, 2013, 18, 1197-1201.	2.3	23
93	Repurposing of statins via inhalation to treat lung inflammatory conditions. Advanced Drug Delivery Reviews, 2018, 133, 93-106.	13.7	23
94	Recent Advances in Controlled Release Pulmonary Therapy. Current Drug Delivery, 2009, 6, 404-414.	1.6	22
95	Preparation andin vitroevaluation of salbutamol-loaded lipid microparticles for sustained release pulmonary therapy. Journal of Microencapsulation, 2012, 29, 225-233.	2.8	22
96	The Effects of Mannitol on the Transport of Ciprofloxacin across Respiratory Epithelia. Molecular Pharmaceutics, 2013, 10, 2915-2924.	4.6	22
97	Dry powder formulation of simvastatin. Expert Opinion on Drug Delivery, 2015, 12, 857-868.	5.0	22
98	Dosing challenges in respiratory therapies. International Journal of Pharmaceutics, 2018, 548, 659-671.	5.2	22
99	Particle Aerosolisation and Break-Up in Dry Powder Inhalers: Evaluation and Modelling of Impaction Effects for Agglomerated Systems. Journal of Pharmaceutical Sciences, 2011, 100, 2744-2754.	3.3	21
100	Co-milled API-lactose systems for inhalation therapy: impact of magnesium stearate on physico-chemical stability and aerosolization performance. Drug Development and Industrial Pharmacy, 2017, 43, 980-988.	2.0	21
101	The achievement of ligand-functionalized organic/polymeric nanoparticles for treating multidrug resistant cancer. Expert Opinion on Drug Delivery, 2017, 14, 937-957.	5.0	21
102	Polymer coating of carrier excipients modify aerosol performance of adhered drugs used in dry powder inhalation therapy. International Journal of Pharmaceutics, 2012, 438, 150-159.	5.2	20
103	Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis. Drug Development and Industrial Pharmacy, 2015, 41, 859-865.	2.0	20
104	Limitations of high dose carrier based formulations. International Journal of Pharmaceutics, 2018, 544, 141-152.	5.2	20
105	Towards the bioequivalence of pressurised metered dose inhalers 2. Aerodynamically equivalent particles (with and without glycerol) exhibit different biopharmaceutical profiles in vitro. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 38-45.	4.3	19
106	The development of a single-use, capsule-free multi-breath tobramycin dry powder inhaler for the treatment of cystic fibrosis. International Journal of Pharmaceutics, 2016, 514, 392-398.	5.2	19
107	The use of fatty acids as absorption enhancer for pulmonary drug delivery. International Journal of Pharmaceutics, 2018, 541, 93-100.	5.2	19
108	Combination of urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate for the treatment of inflammatory lung diseases: An in vitro study. European Journal of Pharmaceutical Sciences, 2018, 120, 96-106.	4.0	19

#	Article	IF	Citations
109	The Contribution of Different Formulation Components on the Aerosol Charge in Carrier-Based Dry Powder Inhaler Systems. Pharmaceutical Research, 2010, 27, 1325-1336.	3.5	18
110	Modelling of molecular phase transitions in pharmaceutical inhalation compounds: An in silico approach. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 78, 83-89.	4.3	18
111	Salbutamol Sulfate Absorption Across Calu-3 Bronchial Epithelia Cell Monolayer is Inhibited in the Presence of Common Anionic NSAIDs. Journal of Asthma, 2013, 50, 334-341.	1.7	18
112	Incorporation of quercetin in respirable lipid microparticles: Effect on stability and cellular uptake on A549 pulmonary alveolar epithelial cells. Colloids and Surfaces B: Biointerfaces, 2013, 112, 322-329.	5.0	18
113	Novel Simvastatin Inhalation Formulation and Characterisation. AAPS PharmSciTech, 2014, 15, 956-962.	3.3	18
114	Allergic environment enhances airway epithelial pro-inflammatory responses to rhinovirus infection. Clinical Science, 2017, 131, 499-509.	4.3	18
115	Inhaled rapamycin solid lipid nano particles for the treatment of Lymphangioleiomyomatosis. European Journal of Pharmaceutical Sciences, 2020, 142, 105098.	4.0	18
116	In-vitro and particle image velocimetry studies of dry powder inhalers. International Journal of Pharmaceutics, 2021, 592, 119966.	5.2	18
117	Artesunate-clindamycin multi-kinetics and site-specific oral delivery system for antimalaric combination products. Journal of Controlled Release, 2010, 146, 54-60.	9.9	17
118	Co-deposition of a triple therapy drug formulation for the treatment of chronic obstructive pulmonary disease using solution-based pressurised metered dose inhalers. Journal of Pharmacy and Pharmacology, 2012, 64, 1245-1253.	2.4	17
119	Is the cellular uptake of respiratory aerosols delivered from different devices equivalent?. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 93, 320-327.	4.3	17
120	Biological Effects of Simvastatin Formulated as pMDI on Pulmonary Epithelial Cells. Pharmaceutical Research, 2016, 33, 92-101.	3.5	17
121	Inhaled simvastatin nanoparticles for inflammatory lung disease. Nanomedicine, 2017, 12, 2471-2485.	3.3	17
122	Microfluidic production of endoskeleton droplets with controlled size and shape. Powder Technology, 2018, 329, 129-136.	4.2	17
123	Delivery of pDNA to lung epithelial cells using PLGA nanoparticles formulated with a cell-penetrating peptide: understanding the intracellular fate. Drug Development and Industrial Pharmacy, 2020, 46, 427-442.	2.0	17
124	The solid-state and morphological characteristics of particles generated from solution-based metered dose inhalers: Influence of ethanol concentration and intrinsic drug properties. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2014, 443, 345-355.	4.7	16
125	Inhalable tranexamic acid for haemoptysis treatment. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 93, 311-319.	4.3	16
126	Mono- and Cocultures of Bronchial and Alveolar Epithelial Cells Respond Differently to Proinflammatory Stimuli and Their Modulation by Salbutamol and Budesonide. Molecular Pharmaceutics, 2015, 12, 2625-2632.	4.6	16

#	Article	IF	Citations
127	Delivery of theophylline as dry powder for inhalation. Asian Journal of Pharmaceutical Sciences, 2015, 10, 520-527.	9.1	16
128	Curcumin Nanoparticles Attenuate Production of Pro-inflammatory Markers in Lipopolysaccharide-Induced Macrophages. Pharmaceutical Research, 2016, 33, 315-327.	3.5	16
129	A Novel Apparatus for the Determination of Solubility in Pressurized Metered Dose Inhalers. Drug Development and Industrial Pharmacy, 2006, 32, 1159-1163.	2.0	15
130	Advances in drug delivery: is triple therapy the future for the treatment of chronic obstructive pulmonary disease?. Expert Opinion on Pharmacotherapy, 2011, 12, 1913-1932.	1.8	15
131	The formulation of a pressurized metered dose inhaler containing theophylline for inhalation. European Journal of Pharmaceutical Sciences, 2015, 76, 68-72.	4.0	15
132	Knowledge that people with intellectual disabilities have of their inhaled asthma medications: messages for pharmacists. International Journal of Clinical Pharmacy, 2016, 38, 135-143.	2.1	15
133	High-Speed Laser Image Analysis of Plume Angles for Pressurised Metered Dose Inhalers: The Effect of Nozzle Geometry. AAPS PharmSciTech, 2017, 18, 782-789.	3.3	15
134	An in vitro model for assessing drug transport in cystic fibrosis treatment: Characterisation of the CuFi-1 cell line. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 156, 121-130.	4.3	15
135	Real-time quantitative monitoring of in vitro nasal drug delivery by a nasal epithelial mucosa-on-a-chip model. Expert Opinion on Drug Delivery, 2021, 18, 803-818.	5.0	15
136	A Review of Electrostatic Measurement Techniques for Aerosol Drug Delivery to the Lung: Implications in Aerosol Particle Deposition. Journal of Adhesion Science and Technology, 2011, 25, 385-405.	2.6	14
137	Comparison of spray congealing and melt emulsification methods for the incorporation of the water-soluble salbutamol sulphate in lipid microparticles. Pharmaceutical Development and Technology, 2013, 18, 266-273.	2.4	14
138	A Novel High-Speed Imaging Technique to Predict the Macroscopic Spray Characteristics of Solution Based Pressurised Metered Dose Inhalers. Pharmaceutical Research, 2014, 31, 2963-2974.	3.5	14
139	Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder. International Journal of Antimicrobial Agents, 2015, 45, 319-323.	2.5	14
140	Aerosol particle generation from solution-based pressurized metered dose inhalers: a technical overview of parameters that influence respiratory deposition. Pharmaceutical Development and Technology, 2015, 20, 897-910.	2.4	14
141	Antibiotic transport across bronchial epithelial cells: Effects of molecular weight, LogP and apparent permeability. European Journal of Pharmaceutical Sciences, 2016, 83, 45-51.	4.0	14
142	Advances in the use of cell penetrating peptides for respiratory drug delivery. Expert Opinion on Drug Delivery, 2020, 17, 647-664.	5.0	14
143	Characterization of Negative Allosteric Modulators of the Calcium-Sensing Receptor for Repurposing as a Treatment of Asthma. Journal of Pharmacology and Experimental Therapeutics, 2021, 376, 51-63.	2.5	14
144	The use of atomic force microscopy to study the conditioning of micronised budesonide. International Journal of Pharmaceutics, 2008, 357, 314-317.	5.2	13

#	Article	IF	Citations
145	Mannitol Delivery by Vibrating Mesh Nebulisation for Enhancing Mucociliary Clearance. Journal of Pharmaceutical Sciences, 2011, 100, 2693-2702.	3.3	13
146	A â€˜soft spotâ€™ for drug transport: modulation of cell stiffness using fatty acids and its impact on drug transport in lung model. Journal of Materials Chemistry B, 2015, 3, 2583-2589.	5.8	13
147	Immunomodulatory Effects of a Low-Dose Clarithromycin-Based Macrolide Solution Pressurised Metered Dose Inhaler. Pharmaceutical Research, 2015, 32, 2144-2153.	3.5	13
148	Temporally and Spatially Resolved x-ray Fluorescence Measurements of in-situ Drug Concentration in Metered-Dose Inhaler Sprays. Pharmaceutical Research, 2016, 33, 816-825.	3.5	13
149	Revealing pMDI Spray Initial Conditions: Flashing, Atomisation and the Effect of Ethanol. Pharmaceutical Research, 2017, 34, 718-729.	3.5	13
150	Development of ciprofloxacin-loaded poly(vinyl alcohol) dry powder formulations for lung delivery. International Journal of Pharmaceutics, 2018, 547, 114-121.	5.2	13
151	On the Use of Computational Fluid Dynamics (CFD) Modelling to Design Improved Dry Powder Inhalers. Pharmaceutical Research, 2021, 38, 277-288.	3.5	13
152	Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract. International Journal of Molecular Sciences, 2022, 23, 2408.	4.1	13
153	Toxicity of curcumin nanoparticles towards alveolar macrophage: Effects of surface charges. Food and Chemical Toxicology, 2022, 163, 112976.	3.6	13
154	Delivery of High Solubility Polyols by Vibrating Mesh Nebulizer to Enhance Mucociliary Clearance. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2012, 25, 297-305.	1.4	12
155	Isothermal calorimetry: A predictive tool to model drug-propellant interactions in pressurized metered dose systems. International Journal of Pharmaceutics, 2014, 461, 301-309.	5.2	12
156	An investigation of surface properties, local elastic modulus and interaction with simulated pulmonary surfactant of surface modified inhalable voriconazole dry powders using atomic force microscopy. RSC Advances, 2016, 6, 25789-25798.	3.6	12
157	The future of inhalers: how can we improve drug delivery in asthma and COPD?. Expert Review of Respiratory Medicine, 2016, 10, 1041-1044.	2.5	12
158	Resveratrol solid lipid microparticles as dry powder formulation for nasal delivery, characterization andin vitrodeposition study. Journal of Microencapsulation, 2016, 33, 735-742.	2.8	12
159	Could simvastatin be considered as a potential therapy for chronic lung diseases? A debate on the pros and cons. Expert Opinion on Drug Delivery, 2016, 13, 1407-1420.	5.0	12
160	Simvastatin Nanoparticles Reduce Inflammation in LPS-Stimulated Alveolar Macrophages. Journal of Pharmaceutical Sciences, 2019, 108, 3890-3897.	3.3	12
161	Microstructural Analysis of Porous Composite Materials: Dynamic Imaging of Drug Dissolution and Diffusion Through Porous Matrices. AAPS Journal, 2008, 10, 560-564.	4.4	11
162	The influence of micronised particulates on the aerosolisation properties of pressurised metered dose inhalers. Journal of Aerosol Science, 2009, 40, 324-337.	3.8	11

#	Article	IF	Citations
163	The formulation, chemical and physical characterisation of clarithromycin-based macrolide solution pressurised metered dose inhaler. Journal of Pharmacy and Pharmacology, 2014, 66, 639-645.	2.4	11
164	The role of direct support professionals in asthma management. Journal of Intellectual and Developmental Disability, 2015, 40, 342-353.	1.6	11
165	Tuning Aerosol Performance Using the Multibreath OrbitalÂ® Dry Powder Inhaler Device: Controlling Delivery Parameters and Aerosol Performance via Modification of Puck Orifice Geometry. Journal of Pharmaceutical Sciences, 2015, 104, 2169-2176.	3.3	11
166	An Investigation into the Powder Release Behavior from Capsule-Based Dry Powder Inhalers. Aerosol Science and Technology, 2015, 49, 902-911.	3.1	11
167	Effect of polyunsaturated fatty acids (PUFAs) on airway epithelial cells' tight junction. Pulmonary Pharmacology and Therapeutics, 2016, 40, 30-38.	2.6	11
168	Sweetening Inhaled Antibiotic Treatment for Eradication of Chronic Respiratory Biofilm Infection. Pharmaceutical Research, 2018, 35, 50.	3.5	11
169	Co-Spray-Dried Urea Cross-Linked Hyaluronic Acid and Sodium Ascorbyl Phosphate as Novel Inhalable Dry Powder Formulation. Journal of Pharmaceutical Sciences, 2019, 108, 2964-2971.	3.3	11
170	In vitro characterization of physico-chemical properties, cytotoxicity, bioactivity of urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate nasal powder formulation. International Journal of Pharmaceutics, 2019, 558, 341-350.	5.2	11
171	The Influence of Actuator Materials and Nozzle Designs on Electrostatic Charge of Pressurised Metered Dose Inhaler (pMDI) Formulations. Pharmaceutical Research, 2014, 31, 1325-1337.	3.5	10
172	Respiratory medication use in an Australian developmental disability clinic population: messages for health care professionals. Australian Journal of Primary Health, 2014, 20, 278.	0.9	10
173	Dynamic electrostatic charge of lactose-salbutamol sulphate powder blends dispersed from a Cyclohaler^{Â®}. Drug Development and Industrial Pharmacy, 2011, 37, 1365-1375.	2.0	9
174	Insights into Spray Development from Metered-Dose Inhalers Through Quantitative X-ray Radiography. Pharmaceutical Research, 2016, 33, 1249-1258.	3.5	9
175	The ability of people with intellectual disability to use inhalers â€“ an exploratory mixed methods study. Journal of Asthma, 2016, 53, 86-93.	1.7	9
176	An automated segmentation framework for nasal computational fluid dynamics analysis in computed tomography. Computers in Biology and Medicine, 2019, 115, 103505.	7.0	9
177	Nasal Powder Formulation of Tranexamic Acid and Hyaluronic Acid for the Treatment of Epistaxis. Pharmaceutical Research, 2020, 37, 186.	3.5	9
178	Development and in vitro-in vivo performances of an inhalable indole-3-carboxaldehyde dry powder to target pulmonary inflammation and infection. International Journal of Pharmaceutics, 2021, 607, 121004.	5.2	9
179	Understanding the effects of aerodynamic and hydrodynamic shear forces on Pseudomonas aeruginosa biofilm growth. Biotechnology and Bioengineering, 2022, 119, 1483-1497.	3.3	9
180	Recent advances in understanding the influence of composite-formulation properties on the performance of dry powder inhalers. Physica B: Condensed Matter, 2007, 394, 315-319.	2.7	8

#	Article	IF	Citations
181	Combining experimental and computational techniques to understand and improve dry powder inhalers. Expert Opinion on Drug Delivery, 2022, 19, 59-73.	5.0	8
182	Development of an In Vivo Ovine Dry Powder Inhalation Model for the Evaluation of Conventional and Controlled Release Microparticles. AAPS Journal, 2009, 11, 465-8.	4.4	7
183	Concurrent oral and inhalation drug delivery using a dual formulation system: the use of oral theophylline carrier with combined inhalable budesonide and terbutaline. Drug Delivery and Translational Research, 2014, 4, 256-267.	5.8	7
184	Investigation into physicalâ€“chemical variables affecting the manufacture and dissolution of wet-milled clarithromycin nanoparticles. Pharmaceutical Development and Technology, 2014, 19, 911-921.	2.4	7
185	Determination of physical and chemical stability in pressurised metered dose inhalers: potential new techniques. Expert Opinion on Drug Delivery, 2015, 12, 1661-1675.	5.0	7
186	The effect of non-specific tight junction modulators on the transepithelial transport of poorly permeable drugs across airway epithelial cells. Journal of Drug Targeting, 2017, 25, 342-349.	4.4	7
187	Assessing Aerosol Performance of a Dry Powder Carrier Formulation with Increasing Doses Using a Novel Inhaler. AAPS PharmSciTech, 2019, 20, 94.	3.3	7
188	Paclitaxel-eluting silicone airway stent for preventing granulation tissue growth and lung cancer relapse in central airway pathologies. Expert Opinion on Drug Delivery, 2020, 17, 1631-1645.	5.0	7
189	Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part II: the effect of nanoparticle charge. Nanomedicine, 2020, 15, 1947-1963.	3.3	7
190	Design, Synthesis, Characterization, and In Vitro Evaluation of a New Cross-Linked Hyaluronic Acid for Pharmaceutical and Cosmetic Applications. Pharmaceutics, 2021, 13, 1672.	4.5	7
191	Micronized drug powders in binary mixtures and the effect of physical properties on aerosolization from combination drug dry powder inhalers. Drug Development and Industrial Pharmacy, 2012, 38, 1504-1511.	2.0	6
192	Evolved gas analysis during thermal degradation of salbutamol sulphate. Journal of Thermal Analysis and Calorimetry, 2015, 120, 789-794.	3.6	6
193	Exploring the impact of sample flowrate on in vitro measurements of metered dose inhaler performance. International Journal of Pharmaceutics, 2016, 514, 420-427.	5.2	6
194	Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part I: the effect of size. Nanomedicine, 2020, 15, 1927-1945.	3.3	6
195	Effect of continuous positive airway pressure treatment on permeability, inflammation and mucus production of human epithelial cells. ERJ Open Research, 2020, 6, 00327-2019.	2.6	6
196	Development and in vitro characterization of a novel pMDI diclofenac formulation as an inhalable anti-inflammatory therapy for cystic fibrosis. International Journal of Pharmaceutics, 2021, 596, 120319.	5.2	6
197	How Do Mechanics Guide Fibroblast Activity? Complex Disruptions during Emphysema Shape Cellular Responses and Limit Research. Bioengineering, 2021, 8, 110.	3.5	6
198	An adaptable microreactor to investigate the influence of interfaces on Pseudomonas aeruginosa biofilm growth. Applied Microbiology and Biotechnology, 2022, 106, 1067-1077.	3.6	6

#	Article	IF	Citations
199	Aerosol Tribocharging and its Relation to the Deposition of Oxisâ„¢ TurbuhalerÂ® in the Electrical Next Generation Impactor. Journal of Pharmaceutical Sciences, 2011, 100, 5270-5280.	3.3	5
200	Twenty years of HFA pMDI patents: facts and perspectives. Journal of Pharmacy and Pharmacology, 2012, 64, 1209-1216.	2.4	5
201	The Effect of Active Pharmaceutical Ingredients on Aerosol Electrostatic Charges from Pressurized Metered Dose Inhalers. Pharmaceutical Research, 2015, 32, 2928-2936.	3.5	5
202	A Simple and Rapid Method for Deposition and Measurement of Drug Transport Across Air Interface Respiratory Epithelia. AAPS PharmSciTech, 2018, 19, 3272-3276.	3.3	5
203	Delivery of pDNA Polyplexes to Bronchial and Alveolar Epithelial Cells Using a Mesh Nebulizer. Pharmaceutical Research, 2019, 36, 14.	3.5	5
204	Validation of a cell integrated next-generation impactor to assess in vitro drug transport of physiologically relevant aerosolised particles. International Journal of Pharmaceutics, 2022, 624, 122024.	5.2	5
205	Development of excipients free inhalable co-spray-dried tobramycin and diclofenac formulations for cystic fibrosis using two and three fluid nozzles. International Journal of Pharmaceutics, 2022, 624, 121989.	5.2	5
206	Modification of Disodium Cromoglycate Passage Across Lung Epithelium In Vitro Via Incorporation into Polymeric Microparticles. AAPS Journal, 2012, 14, 79-86.	4.4	4
207	Preparation and Evaluation of Single and Co-Engineered Combination Inhalation Carrier Formulations for the Treatment of Asthma. Journal of Pharmaceutical Sciences, 2012, 101, 4267-4276.	3.3	4
208	The Effect of Actuator Nozzle Designs on the Electrostatic Charge Generated in Pressurised Metered Dose Inhaler Aerosols. Pharmaceutical Research, 2015, 32, 1237-1248.	3.5	4
209	Investigation into the Manufacture and Properties of Inhalable High-Dose Dry Powders Produced by Comilling API and Lactose with Magnesium Stearate. AAPS PharmSciTech, 2017, 18, 2248-2259.	3.3	4
210	Using individualized three-dimensional printed airway models to guide airway stent implantation. Interactive Cardiovascular and Thoracic Surgery, 2020, 31, 900-903.	1.1	4
211	Novel nano-cellulose excipient for generating non-Newtonian droplets for targeted nasal drug delivery. Drug Development and Industrial Pharmacy, 2017, 43, 1729-1733.	2.0	4
212	Timothy Grass Pollen Induces Spatial Reorganisation of F-Actin and Loss of Junctional Integrity in Respiratory Cells. Inflammation, 2022, 45, 1209-1223.	3.8	4
213	The Formation of Aerosol Particles from Solution-Based Pressurized Metered Dose Inhalers and Implications of Incomplete Droplet Drying: Theoretical and Experimental Comparison. Aerosol Science and Technology, 2015, 49, 1090-1099.	3.1	3
214	Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment?. Expert Opinion on Orphan Drugs, 2018, 6, 69-84.	0.8	3
215	Effect of Dosing Cup Size on the Aerosol Performance of High-Dose Carrier-Based Formulations in a Novel Dry Powder Inhaler. Journal of Pharmaceutical Sciences, 2019, 108, 949-959.	3.3	3
216	The Development and Validation of anIn VitroAirway Model to Assess Realistic Airway Deposition and Drug Permeation Behavior of Orally Inhaled Products Across Synthetic Membranes. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2018, 31, 103-108.	1.4	3

#	Article	IF	Citations
217	Spray freeze drying for protein encapsulation: Impact of the formulation to morphology and stability. Drying Technology, 2023, 41, 137-150.	3.1	3
218	Effect of Moisture on the Compressibility and Compactibility of Sodium Starch Glycolate. Pharmaceutical Development and Technology, 2007, 12, 217-222.	2.4	2
219	Determination of Reference Ultrasound Parameters for Model and Hydrofluoroalkane Propellants Using High-Resolution Ultrasonic Spectroscopy. AAPS PharmSciTech, 2008, 9, 605-611.	3.3	2
220	Computational and visualization approaches in respiratory delivery. Advanced Drug Delivery Reviews, 2012, 64, 295.	13.7	2
221	Image-based ciliary beating frequency estimation for therapeutic assessment on defective mucociliary clearance diseases. , 2014, , .		2
222	The Effects of Loaded Carrier Mass and Formulation Mass on Aerosolization Efficiency in Dry Powder Inhaler Devices. Current Drug Delivery, 2015, 12, 40-46.	1.6	2
223	Human Stimulus Factor Is a Promising Peptide for Delivery of Therapeutics. Journal of Pharmaceutical Sciences, 2019, 108, 1401-1403.	3.3	2
224	Co-delivery of inhalable therapies: Controlling active ingredients spatial distribution and temporal release. Materials Science and Engineering C, 2021, 122, 111831.	7.3	2
225	Tobramycin and Colistin display anti-inflammatory properties in CuFi-1 cystic fibrosis cell line. European Journal of Pharmacology, 2021, 902, 174098.	3.5	2
226	Application of Micro-Engineered Kidney, Liver, and Respiratory System Models to Accelerate Preclinical Drug Testing and Development. Bioengineering, 2022, 9, 150.	3.5	2
227	The application of in vitro cellular assays for analysis of electronic cigarettes impact on the airway. Life Sciences, 2022, 298, 120487.	4.3	2
228	Protective Abilities of an Inhaled DPI Formulation Based on Sodium Hyaluronate against Environmental Hazards Targeting the Upper Respiratory Tract. Pharmaceutics, 2022, 14, 1323.	4.5	2
229	Quality of Inhalation Products: Specifications. , 2013, , 169-190.		1
230	Graphing software for medical writers. Medical Writing, 2014, 23, 41-44.	0.1	1
231	Unique location but similar issues: working with health professionals in correctional services to improve inhaler use. Journal of Pharmacy Practice and Research, 2015, 45, 276-281.	0.8	1
232	Beating cilia identification in fluorescence microscope images for accurate CBF measurement. , 2015, , .		1
233	The Development and Achievement of Polymeric Nanoparticles for Cancer Drug Treatment. , 2017, , 25-82.		1
234	Selective shape-change response by anisotropic endoskeletal droplets. Extreme Mechanics Letters, 2020, 35, 100618.	4.1	1

#	Article	IF	Citations
235	Particle Image Velocimetry Measurements of a Dry Powder Inhaler Flow. International Symposium on Particle Image Velocimetry, 2021, 1, .	0.1	1
236	Controlled release antibiotics for dry powder lung delivery. Drug Development and Industrial Pharmacy, 2009, 00, 090805050810080-8.	2.0	1
237	Prospective nanoparticle treatments for lymphangioleiomyomatosis. Expert Opinion on Drug Delivery, 2022, 19, 75-86.	5.0	1
238	Themed Issue: Inhalation Pharmaceutics â€“ Current Technologies and Approaches to Respiratory Drug Delivery. Journal of Pharmacy and Pharmacology, 2012, 64, 1207-1208.	2.4	0
239	Investigating potential TRPV1 positive feedback to explain TRPV1 upregulation in airway disease states. Drug Development and Industrial Pharmacy, 2022, , 1-11.	2.0	0